

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

30th March, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”) - Intimation for incorporation of Wholly Owned Subsidiary of the Company as a ‘Scientific Office’.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that a Wholly Owned Subsidiary of the Company as a ‘Scientific Office’ (“WOS”) in the name of ‘Alkem Pharmaceuticals Scientific Office FZ LLC’ has been incorporated in Dubai Healthcare City, UAE.

Particulars of the disclosure required under SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure – I.

Kindly take the same on your records.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Annexure – I

Sr. No.	Particulars	Details
a.	Name of target entity, details in brief such as size, turnover etc.	<p>Name of WOS: Alkem Pharmaceuticals Scientific Office FZ LLC (“Alkem Pharmaceuticals”)</p> <p>Authorized Share Capital of WOS: AED 3,670,000 divided into 3,670 Equity Shares of AED 1,000 each.</p> <p>Subscribed Capital of WOS: AED 3,670,000 divided into 3,670 Equity Shares of AED 1,000 each.</p> <p>Turnover: Not Applicable</p>
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Alkem Pharmaceuticals, being a WOS, is a related party of Alkem Laboratories Limited (“ Company ”).
c.	Industry to which the entity being acquired belongs	Pharmaceuticals
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Alkem Pharmaceuticals has been incorporated to undertake the activities of manufacturing products and obtaining product registrations, except trading activities.
e.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f.	Indicative time period for completion of the acquisition	Not Applicable
g.	Consideration – whether cash consideration or share swap or any other form and details of the same	Cash
h.	Cost of acquisition and/or the price at which the shares are acquired	Subscription of 3,670 Equity Shares of AED 1,000 each amounting to AED 3,670,000.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

i.	Percentage of shareholding / control acquired and / or number of shares acquired	100%
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief Background: Alkem Pharmaceuticals has been incorporated to undertake the activities of manufacturing products and obtaining product registrations, except trading activities.</p> <p>Date of Incorporation: 4th February, 2026</p> <p>Country: UAE</p> <p>Least 3 years Turnover: Not Applicable</p>

Note: Related approvals from UAE's Ministry of Health and Prevention are delayed presumably due to the ongoing regional conflict.